These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14698141)

  • 21. Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy.
    Shu S; Zheng R; Lee WT; Cohen PA
    Crit Rev Immunol; 2007; 27(5):463-83. PubMed ID: 18197808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
    Xia D; Li F; Xiang J
    Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
    Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
    Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fusion vaccine therapy by IL-2-gene-transduced dendritic cells and tumor cells].
    Ogawa F; Iinuma H; Iwasaki K; Tamura J; Kumagai H; Inaba T; Fukushima R; Kota O
    Gan To Kagaku Ryoho; 2005 Oct; 32(11):1580-2. PubMed ID: 16315876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific antitumor effects of tumor vaccine produced by electrofusion between osteosarcoma cell and dendritic cell in rats.
    Yu Z; Fan Q; Hao X; Long H
    Cell Mol Immunol; 2004 Dec; 1(6):454-60. PubMed ID: 16293215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms.
    Okada H; Tahara H; Shurin MR; Attanucci J; Giezeman-Smits KM; Fellows WK; Lotze MT; Chambers WH; Bozik ME
    Int J Cancer; 1998 Oct; 78(2):196-201. PubMed ID: 9754652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
    Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
    Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
    Dolan BP; Gibbs KD; Ostrand-Rosenberg S
    J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
    Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
    Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo.
    Kim GY; Chae HJ; Kim KH; Yoon MS; Lee KS; Lee CM; Moon DO; Lee JS; Jeong YI; Choi YH; Park YM
    Biosci Biotechnol Biochem; 2007 Jan; 71(1):215-21. PubMed ID: 17213658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of antitumor immunity by semi-allogeneic and fully allogeneic electrofusion products of tumor cells and dendritic cells.
    Siders WM; Garron C; Shields J; Kaplan JM
    Clin Transl Sci; 2009 Feb; 2(1):75-9. PubMed ID: 20443871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity.
    Todo T; Martuza RL; Dallman MJ; Rabkin SD
    Cancer Res; 2001 Jan; 61(1):153-61. PubMed ID: 11196154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction.
    Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
    Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic tumor vaccine produced by electrofusion between osteosarcoma cell line and dendritic cells in the induction of antitumor immunity.
    Yu Z; Ma B; Zhou Y; Zhang M; Long H; Wang Y; Fan Q
    Cancer Invest; 2007; 25(7):535-41. PubMed ID: 17952746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
    da Cunha A; Antoniazi Michelin M; Cândido Murta EF
    Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.